Sofosbuvir

CHEMBL1259059 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

529.5 g/mol

LogP

1.0

Phase

4

A cornerstone of modern hepatitis C treatment, this once-daily antiviral blocks a key enzyme the hepatitis C virus needs to copy itself. When combined with other antivirals, it achieves cure rates above 95% in most patients after just 8 to 12 weeks of treatment, with minimal side effects.

Masse moléculaire

529,5000 g/mol

LogP

1,00

TPSA

153,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Hypertension HIV/AIDS Hepatitis C Heart Failure Cardiovascular Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1

InChI

InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1

Molecular Formula

C22H29FN3O9P

HBD / HBA

3 / 11

Liaisons Rotatives

11

Atomes Lourds

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A cornerstone of modern hepatitis C treatment, this once-daily antiviral blocks a key enzyme the hepatitis C virus needs to copy itself. When combined with other antivirals, it achieves cure rates above 95% in most patients after just 8 to 12 weeks of treatment, with minimal side effects.

Yes, Sofosbuvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1259059. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 45375808. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Sofosbuvir sur PillFYI

Structure

Données Clés

Formule: C22H29FN3O9P
Synonymes: 8

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.